Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Bank Regulation Rollbacks in the U.S. and UK Could Increase Financial Risks, Study Warns 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Asian Stocks Sink as Apple Price Hikes Spark AI Valuation Fears, South Korea and Japan Lead Selloff 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
The Japanese Ministry of Health, Labor and Welfare has granted priority review status to the Alzheimer’s disease drug, lecanemab, of Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc.
Once the priority status has been granted, the target total review period is shortened.
Lecanemab was recently granted accelerated approval in the US.
A late-stage study showed the drug reduced the rate of cognitive decline in patients with early Alzheimer’s by 27 percent, compared with a placebo.
Similar experimental medications have largely all failed in the past.
Eisai also requested complete U.S. approval of the medication earlier this month. Food and Drug Administration (FDA) as a treatment for patients with neurodegenerative disease in its early stages.
